The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05312151 |
Recruitment Status :
Active, not recruiting
First Posted : April 5, 2022
Last Update Posted : April 9, 2024
|
Sponsor:
COMPASS Pathways
Information provided by (Responsible Party):
COMPASS Pathways
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | March 28, 2022 | ||||
First Posted Date ICMJE | April 5, 2022 | ||||
Last Update Posted Date | April 9, 2024 | ||||
Actual Study Start Date ICMJE | June 10, 2022 | ||||
Actual Primary Completion Date | December 19, 2023 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Safety [ Time Frame: Up to 12 weeks ] Proportion of patients with adverse events (AEs)
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | ||||
Official Title ICMJE | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | ||||
Brief Summary | The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder | ||||
Detailed Description | The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Post Traumatic Stress Disorder | ||||
Intervention ICMJE | Drug: Psilocybin
Open label
Other Name: COMP360
|
||||
Study Arms ICMJE | Experimental: COMP360 Psilocybin
25 mg COMP360 Psilocybin
Intervention: Drug: Psilocybin
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Actual Enrollment ICMJE |
22 | ||||
Original Estimated Enrollment ICMJE |
20 | ||||
Estimated Study Completion Date ICMJE | April 2024 | ||||
Actual Primary Completion Date | December 19, 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Key Inclusion Criteria:
Key Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | United Kingdom, United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT05312151 | ||||
Other Study ID Numbers ICMJE | COMP201 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | COMPASS Pathways | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | COMPASS Pathways | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | COMPASS Pathways | ||||
Verification Date | April 2024 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |